Jan 11, 2022

Kallelse till extra bolagsstämma i ondosis ab

Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till extra bolagsstämma tisdagen den 25 januari 2022 kl. 15.00 i Bolagets lokaler på Pepparedsleden 1 i Mölndal.

Notice of extra general meeting in ondosis ab

The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby invited to the extra general meeting on Tuesday 25 January 2022 at 15.00 CET at the Company's premises at Pepparedsleden 1 in Mölndal.

New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.

OnDosis completes a private placement of SEK 92 million led by Aeternum Capital

OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.

New business partner and international recognition for OnDosis

OnDosis wants to revolutionize the way we take our medicines. The idea is that every single patient, in the easiest possible way, shall get precisely the right amount of medicine and thus lead a better life. Now the company begins a cooperation with Opatus, whose digital tool objectively scales symptoms of ADHD patients. In addition, OnDosis recently received a double recognition at the largest conference concerning ADHD and related diseases in USA—and there is a growing interest in the company in other areas too.

OnDosis announces commitment of 30 MSEK raise from existing owners and DIG Investment

Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.

OnDosis selected to pitch at European Angel Investment Summit

This week, OnDosis is one of 40 startups who will get to pitch in front of investors from all over the world at European Angel Investment Summit in Brussels 25–26 November. In addition, we're participating at The 29th MedTech Investing Europe Conference in London 26–27 November. Read more: http://europeanangelsummit.com/startups/ http://www.medtechinvesting.com/

Nov 15, 2019

Major article on the opportunities with On Dosis in IPI Magazine

Pharmaceutical innovation is accelerating fast, but the way of dosing oral medicines to patients has very much stayed the same. This article in IPI magazine, “Beyond the Pill Personalisation by Integrating Oral Medication and Digitalisation”, highlights the opportunities with OnDosis.

OnDosis awarded Horizon 20/20 funding and attending key meetings to broaden partnerships

During the first half of 2019 OnDosis was awarded a European Union’s Horizon 2020 Research and Innovation Programme SME (Small and Medium sized Enterprises) instrument for phase 1. This will help OnDosis progress the work in developing its product for ADHD. Supporting its connectivity interface OnDosis has also been contracted by a EUREKA cluster 5G project.

Shaping the journey of a new life science company?

After two successful years since being founded, OnDosis is accelerating. We are now looking for a Co-Pilot to the CEO, a position which will be critical in order to drive the company towards our ambition. We are looking for an energetic doer. A person that is making things happen, connecting dots and building relationships. This individual will grow with OnDosis and be part of a small but dynamic leadership team. Is it you?

OnDosis has been chosen as one of the companies selected to the Swedish IVA 100 list

The IVA (Royal Swedish Academy of Engineering Sciences) is an independent academy whose mission is “...to promote the engineering and economic sciences and the advancement of business and industry for the benefit of society”. IVA’s list brings together research that can form the basis of innovation in the form of new companies, new products and services, business development or other form of benefit.

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.

Introducing OnDosis, a new life science company

Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.